• Comparison of the evolution of the lipid profile between the two treatment groups, from baseline to Week 12, evaluated on: Plasma triglyceride level changes [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• Plasma direct measured low-density lipoprotein cholesterol (LDL-CHO) [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• The changes in high-density lipoprotein cholesterol (HDL-CHO), and total cholesterol (T-CHO) levels [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• The changes in T-CHO/ HDL-CHO and HDL-CHO/LDL-CHO ratios [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• The percentage of patients with plasma triglycerides greater than 10 g/L at Week 12 [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• The percentage of patients with plasma HIV-1 viral load less than 400 copies/mL at Week 12 (virological control) [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• The percentage of patients with a plasma HIV-1 viral load greater than 400 copies/mL at Week 12 (virological therapy failure). The genotype of HIV-1 will be analyzed in case of failure [ Time Frame: Through 12 weeks ] [ Designated as safety issue: No ]
• The changes of cluster determinant 4 (CD4) cell counts from baseline [ Time Frame: Through 48 weeks ] [ Designated as safety issue: No ]

• Comparison of the evolution of the lipid profile between the two treatment groups, from baseline to Week 12, evaluated on:
• Plasma direct measured LDL-CHO
• The changes in HDL-CHO, and T CHO levels.
• The changes in T-CHO/ HDL-CHO and HDL-CHO/LDL-CHO ratios.
• The percentage of patients with plasma triglycerides greater than 10 g/L at Week 12.
• The percentage of patients with plasma HIV-1 viral load less than 400 copies /mL at Week 12 (virological control).
• The percentage of patients with a plasma HIV-1 viral load greater than 400 copies/mL at Week 12 (virological therapy failure). The genotype of HIV 1 will be analyzed in case of failure.
• The changes of cluster determinant 4 (CD4) cell counts from baseline
• Plasma triglycerides levels changes

This study looks at lipid changes in HIV infected patients when they are switched from existing HIV treatment to a treatment containing Truvada.

This is a Phase IV, multicenter (in France) and open label study. The study is conducted in two phases, a comparative randomized phase, which serves the primary objective of the study, and a follow up phase.

Phase 1, Day-14 to Week12: patients will be, on a 1:1 basis, randomized to two arms: A. the TVD group (substitution of their current NRTIs by TVD [TDF+FTC] with continuation of their current NNRTI or PI at the same dose) or B. a control group (continuation of previous HAART regimen). This phase of the study serves the Primary objective of the study.

Phase 2, roll-over follow-up, Week 12 to Week 48: Patients in the TVD group (Arm A) continue with TVD + an NNRTI or PI. Patients who did not switch in Phase 1 to TVD (Arm B) will be proposed to switch in this phase of the study.

Patients will be assessed for efficacy and safety during both phases of the study.

• Drug: Truvada
• Drug: Current HAART regimen

• Experimental: Phase 1, Day-14 to Week12:the TVD group (substitution of their current NRTIs by TVD [TDF+FTC] with continuation of their current NNRTI or PI at the same dose)
• Active Comparator: Phase 1, Day-14 to Week12: a control group (continuation of previous HAART regimen)
• Experimental: Phase 2, roll-over follow-up, Week 12 to Week 48: Patients in the TVD group (Arm A) continue with TVD + an NNRTI or PI. Patients who did not switch in Phase 1 to TVD (Arm B) will be proposed to switch in this phase of the study.

Inclusion Criteria:

• Patients displaying abnormal plasma lipid levels
• Patients with stable highly active antiretroviral therapy (HAART)